Company in brief

Company in brief

Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and is committed to bringing innovation to patients with an unmet need and improving patient lives.

Commercial launch

The lead product candidate melflufen is currently being reviewed by the U.S. Food and Drug Administration, FDA, as a potential treatment for multiple myeloma. The FDA has granted the New Drug Application for melflufen a priority review and set a target date for a decision to February 28, 2021. The company is planning for a commercial launch in the US in the beginning of 2021.

Evolving PDC-platform

Melflufen is the first drug candidate coming out of the company´s proprietary Peptide Drug Conjugate platform, PDC. Oncopeptides has recently submitted an Investigational New Drug application for its second drug candidate from this technology platform, OPD5.

Oncopeptides on Nasdaq February 2017

Oncopeptides has established a new facility for pre-clinical drug development in Solna, Sweden, which provides adequate resources to further expand the development of the PDC-platform and generate new drug candidates.

Footprint in leading biotech hubs

The global headquarters is in Stockholm, Sweden, and the U.S. headquarters in Waltham, Massachusetts, outside of Boston. In addition, the company has an office in Los Altos, California.

Oncopeptides AB (publ) has 250 employees and is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more

Strategy

Following a potential approval by the FDA, our strategy is to commercialize melflufen in the US with our own organization.

Read more

Governance structure

Oncopeptides’ corporate governance has, prior to the listing on Nasdaq Stockholm, been governed by the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)), the Swedish Annual Accounts Act (Sw. årsredovisningslagen (1995:1554)) and other applicable laws and regulations, the Company’s articles of association and internal policy documents.

Read more